Market Research Logo

Bronchiectasis - Pipeline Review, H2 2015

Bronchiectasis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Bronchiectasis - Pipeline Review, H2 2015’, provides an overview of the Bronchiectasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bronchiectasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Bronchiectasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Bronchiectasis Overview
Therapeutics Development
Pipeline Products for Bronchiectasis - Overview
Bronchiectasis - Therapeutics under Development by Companies
Bronchiectasis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bronchiectasis - Products under Development by Companies
Bronchiectasis - Companies Involved in Therapeutics Development
Alitair Pharmaceuticals, Inc.
Bayer AG
Grifols, S.A.
Kamada Ltd.
Nostrum Pharmaceuticals, LLC
Pulmatrix, Inc.
Recipharm AB
Savara Inc.
Serendex Pharmaceuticals A/S
Therabron Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated
Bronchiectasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles alpha-1 proteinase inhibitor (human) second generation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALT-09 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARD-3150 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY-858501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CG-1011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ciprofloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dapsone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
doxofylline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erdosteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leukotriene B4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levofloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PB-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vancomycin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VX-371 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bronchiectasis - Recent Pipeline Updates
Bronchiectasis - Dormant Projects
Bronchiectasis - Discontinued Products
Bronchiectasis - Product Development Milestones
Featured News & Press Releases
Oct 13, 2015: Aradigm Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis
Sep 22, 2015: Aradigm Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
Sep 02, 2015: Pulmatrix Issued New Composition of Matter Patent Covering iSPERSE Technology
Aug 09, 2015: Serendex to initiate first phase II clinical trial
May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced
May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical’s inhalable biological drug for treatment of severe pulmonary diseases
May 10, 2015: Positive topline data from Serendex phase I clinical trial
Feb 27, 2015: Serendex submits phase I application
Jan 14, 2015: Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia
Nov 24, 2014: FDA Grants QIDP Designation to Bayer's Ciprofloxacin Dry Powder for Inhalation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Bronchiectasis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Bronchiectasis - Pipeline by Alitair Pharmaceuticals, Inc., H2 2015
Bronchiectasis - Pipeline by Bayer AG, H2 2015
Bronchiectasis - Pipeline by Grifols, S.A., H2 2015
Bronchiectasis - Pipeline by Kamada Ltd., H2 2015
Bronchiectasis - Pipeline by Nostrum Pharmaceuticals, LLC, H2 2015
Bronchiectasis - Pipeline by Pulmatrix, Inc., H2 2015
Bronchiectasis - Pipeline by Recipharm AB, H2 2015
Bronchiectasis - Pipeline by Savara Inc., H2 2015
Bronchiectasis - Pipeline by Serendex Pharmaceuticals A/S, H2 2015
Bronchiectasis - Pipeline by Therabron Therapeutics, Inc., H2 2015
Bronchiectasis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Bronchiectasis Therapeutics - Recent Pipeline Updates, H2 2015
Bronchiectasis - Dormant Projects, H2 2015
Bronchiectasis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Bronchiectasis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report